Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Research Council grant · Running

FORCE Formaldehyde crosslink exposure and genomic ageing

Coordinator
The Chancellor, Masters and Scholars of the University of Oxford, United Kingdom
Runs
1 January 2027 to 31 December 2031
Status
Running
EU funding
€2.7m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101264912

What the project is doing

In the project's own words, from its summary on CORDIS.

DNA repair pathways are essential for human health and longevity. While their molecular mechanisms are well defined, their physiological roles across tissues remain less understood. Our foundational research identified a major source of endogenous DNA damage: reactive aldehydes such as acetaldehyde (from ethanol) and formaldehyde (from metabolism and diet), which generate toxic DNA crosslinks in the blood, brain, and kidney.

To counter this, cells rely on a two-tier protection system. Tier 1 enzymes (ALDH2 and ADH5) detoxify aldehydes. Tier 2 repairs the damage aldehydes cause via the Fanconi anaemia (FA) pathway or transcription-coupled repair (TCR). Loss of either of these second-tier pathways leads to tissue-specific degeneration, as seen in FA, where blood is most affected, and Cockayne syndrome (CS), where kidney and brain degeneration dominate.

In FORCE (Formaldehyde Crosslink Exposure in Genomic Ageing), we build on these discoveries to explore how non-haematopoietic tissues respond to crosslink damage. Using our novel SWITCH mouse models, where Tier 1 detoxification is restricted to blood, we bypass early lethality to reveal hidden vulnerabilities in other tissues. In SWITCH FA-deficient animals, the liver fails due to extreme hepatocyte polyploidy, yet – surprisingly - the rapidly renewing intestine remains unaffected.

We will investigate the mechanisms behind hepatic failure and the unexpected resilience of enterocytes, aiming to identify new aldehyde-protective pathways. By contrast, in SWITCH TCR-deficient models, blood-borne formaldehyde detoxification protects against neurodegeneration and kidney failure. We will map the aldehyde-sensitive cell types and examine how systemic clearance preserves tissue function. Finally, we will screen for small molecules that reduce aldehyde toxicity, laying the foundation for new therapies against age-related decline driven by endogenous metabolic damage.

Topics

Who is involved

OrganisationCityCountryRole
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI